Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

NCT00323791 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

100

Enrollment

OTHER

Sponsor class

Stopped slow accrual

Conditions

Kidney Cancer

Interventions

DRUG: gemcitabine hydrochloride
DRUG: imatinib mesylate
GENETIC: gene expression analysis
GENETIC: protein expression analysis
OTHER: immunohistochemistry staining method
OTHER: laboratory biomarker analysis

Sponsor

University of Medicine and Dentistry of New Jersey

Collaborators

[object Object]